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Introduction: Acute muscle wasting in the critically ill is common and associated with significant morbidity and
mortality. Although some aetiological factors are recognised and muscle wasting can be detected early with
ultrasound, it not possible currently to predict in advance of muscle loss those who will develop muscle wasting.
The ability to stratify the risk of muscle wasting associated with critical illness prior to it becoming clinically
apparent would provide the opportunity to predict prognosis more accurately and to intervene at an early stage.
MicroRNAs are small non-coding RNAs that modulate post-transcriptional regulation of translation, some are tissue
specific and can be detected and quantified in plasma. We hypothesised that certain plasma microRNAs could be
biomarkers of ICU acquired muscle weakness.
Methods: Plasma levels of selected microRNAs were measured in pre- and post-operative samples from a previously
reported prospective observational study of 42 patients undergoing elective high-risk cardiothoracic surgery, 55% of
whom developed muscle wasting.
Results: The rise in miR-181a was significantly higher on the second post-operative day in those who developed
muscle wasting at 1 week compared to those who did not (p = 0.03). A rise in miR-181a of greater than 1.7 times
baseline had 91% specificity and 56% sensitivity for subsequent muscle wasting. Other microRNAs did not show
significant differences between the groups.
Conclusion: Plasma miR-181a deserves further investigation as a potential biomarker of muscle wasting. Additionally,
since mir-181a is involved in both regulation of inflammation and muscle regeneration and differentiation; our
observation therefore also suggests directions for future research.Introduction
Acute muscle wasting following critical illness is a com-
mon clinical problem [1], which is associated with sig-
nificant morbidity and mortality [2]. Damage to muscle
function and structure starts in the acute phase of the
clinical illness [3,4]. The muscle wasting and consequent
loss of strength that results from critical illness varies
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unless otherwise stated.tients who are intubated for a week or more, 25% have
significant muscle weakness at awakening [5], but in the
worst cases patients may become severely disabled re-
quiring long-term respiratory weaning and developing a
long-lasting neuromuscular deficit [6].
Muscle wasting and weakness although related are not
directly comparable, however, the ability to predict the
development of muscle wasting prior to its development,
or before the patient can be assessed for weakness would
enable clinicians to predict prognosis, direct early re-
habilitation and guide management, which may in the
future include anabolic drugs [7]. Although early muscle
wasting can be detected with ultrasound [4] this may be
unavailable or technically challenging and therefore a
circulating biomarker would have significant advantages,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Bloch et al. Critical Care  (2015) 19:147 Page 2 of 7especially if changes preceded loss of muscle cross-
sectional area. Lastly a predictive biomarker of acute
muscle wasting would facilitate selection of high-risk
patients and thus, allow enrichment of stratified medi-
cine trials.
MicroRNAs are small non-coding RNAs that modify
translation. Many are tissue-specific and can be quanti-
fied reliably and reproducibly in blood [8-10]. The role
of microRNAs in the pathogenesis of disease is a fast
expanding area of research. However, their potential use
as biomarkers is also increasingly recognised, as they cir-
culate in blood, are often tissue-specific and are resistant
to breakdown as they are believed to circulate in pro-
tective exosomes [10,11], for example, as prognostic and
diagnostic markers in acute coronary syndromes [9] and
in diagnosis of solid and haematological cancers [11].
Our group has previously shown that blood microRNA
profile reflects muscle phenotype and muscle atrophy in
chronic obstructive pulmonary disease (COPD) [12,13].
Therefore, we hypothesised that muscle-specific micro-
RNAs, which are known to be involved in muscle
homeostasis and metabolism (1,133,206,499 [14]) and
have been found to be associated with muscle wasting
by our group [12,13], as well as those involved in the
regulation of muscle regeneration and inflammation
(30b, 181a - believed to be the major member of the 181
family functional in muscle [14,15]) might prove to be
useful biomarkers of early development of acute muscle
wasting in the critically ill patient. Last, the role for these
microRNAs in particular as a biomarker was suggested by
our recent observation that muscle expression of these
microRNAs is reduced in patients with established ICU-
acquired muscle wasting [16].
Material and methods
Patient recruitment and study design
Blood from a previously reported prospective observa-
tional study was used [17]. Briefly patients undergoing a
high-risk elective procedure requiring post-operative ad-
mission to adult critical care were recruited. Patients in-
volved in the study gave informed written consent to
take part. The study was ethically approved by the local
research ethics committee approval under the National
Institute for Health Research (NIHR) Respiratory Bio-
medical Research Unit (BRU) at the Royal Brompton
and Harefield National Health Service (NHS) trust
(10/H0504/9). High-risk patients were defined by the
surgical team and EuroSCORE assessment [18]. Malig-
nancy, pre-existing muscle or neuromuscular disease, or
contraindication to serial blood sampling excluded patients
from the study. Measurement of the cross-sectional area
of the right rectus femoris muscle by ultrasound (US RFcsa)
(see below) was used to assess quadriceps muscle mass
pre-operatively, on the day before surgery. This wasrepeated at day 7 of admission or on discharge from hos-
pital if earlier than day 7. Bloods were taken pre-
operatively for analysis (baseline), on the 1st (D1) and 2nd
(D2) post-operative days and at day 7 or at discharge from
hospital if earlier (D7). D7 and discharge earlier than day 7
were considered and analysed as the same time point: this
only applied to three patients in the non muscle-wasting
group and one in the muscle-wasting group. Following
centrifuge separation of plasma (1,500 g for 10 minutes)
samples were aliquoted and stored at −80°C within 2 hours
of collection.
Definition of quadriceps wasting by measurement of
cross-sectional area of the rectus femoris by ultrasound
B-mode ultrasound (US) imaging with a 10-MHz 12 L-RS
probe was used (Logiq E, GE Healthcare, Buckinghamshire,
UK) to measure the US RFcsa as previously described
[17,19,20]. Three separate images were obtained and the
RFcsa estimated using Image-J software (National Institutes
of Health, USA). Either the point 2/3 or 4/5 of the distance
from the anterior superior iliac spine to the superior border
of the patella (both points have been validated by our
group) was used to measure the US RFcsa, and the same
point measured for repeated measures. The mean of these
three measurements was used. Images were excluded
(n = 3) if the edges of the RF muscle could not be de-
fined well enough to calculate the RFcsa, for example if
the patient was very oedematous. Patients were classified
as those who developed muscle wasting if they developed
more than 9.24% muscle wasting, as determined by the
previously calculated coefficient of variation, based on the
reproducibility of the measure in preliminary studies [17].
Plasma microRNA extraction and quantification
In order to provide normalisation for the RNA extraction
process we spiked in an exogenous control (Caenorhabdi-
tis elegans microRNA, C-39). Quantification of micro-
RNAs in plasma and normalisation to a spiked in control
has been previously described [21]. RNA was extracted
with TRIzol® Reagent (Invitrogen) and miRNAeasy RNA
and small RNA extraction kits (Qiagen). MicroRNAs were
quantified using NCODE™ VILO™ miRNA cDNA synthe-
sis and sybr-green qPCR kits (Invitrogen). Full details of
these methods, including primers used, have been previ-
ously published by our group [12]. Samples were excluded
if the PCR melt curves suggested multiple products or du-
plicates were inconsistent. Excluded samples were equally
distributed between both groups (non muscle-wasting
group 48/380 and in the muscle-wasting group 57/460,
P = 0.91,chi-squared test).
Data and statistical analysis
MicroRNA data were non-parametrically distributed; as
such the data are presented as median with IQR. Repeated
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tiple comparisons (all time points to the pre-operative
baseline) was used for within-group analysis. The
Kolmogorov-Smirnov (KS) test was used for the between-
group analysis of miR-181a fold-change, as the variance
was different between the groups. Statistical analysis
and figure construction was carried out using Graph-
pad PRISM 6 (GraphPad Software, San Diego, CA,
USA). Receiver operating characteristic (ROC) curve
analysis and calculation of specificity and sensitivity
were carried out using Graphpad PRISM 6. Positive
predictive value and negative predictive value were calcu-
lated using www.medcalc.org.
Results
Patients
The demographic data and clinical characteristics of this
patient cohort have been previously published [17]. Of
the 42 patients included in the data analysis 55% (n = 23)
developed muscle wasting. Those who developed muscle
wasting and those who did not were well-matched in
terms of age, sex, body mass index, co-morbidities andTable 1 Demographic data, co-morbidities and critical care da
patients (n = 23)
Non muscle-wasting
patients(n = 19)
Demographic data
Age, years 65.7 ± 17.2
Sex, male/female 9/10
Body mass index, kg/m2a 26.6 ± 4.6
EuroSCORE 5.3 ± 1.8
Pre-operative creatinine, umol/La 81.3 ± 23.6
Pre-operative creatinine clearance, ml/minutea 84.7 ± 36.1
Pre-operative co-morbidities, n
Ischaemic heart disease 10
Structural heart disease 9
Dysrhythmia 2
Systemic hypertension 7
Pulmonary hypertension 1
Hypercholesterolaemia 7
Congenital cardiac disease 3
Diabetes 3
Obstructive lung disease 3
Outcome data
C-reactive protein day 2 165 ± 60
ICU length of stay, days, median (IQR) 1 (1 to 2.5)
Hospital length of stay, days, median (IQR) 8 (7 to 11)
Data presented as mean ± SD unless otherwise stated. aWeight unavailable for two
previously published study [17]. p values calcultated by t-test, # - Man-Whitney or *surgical risk (EuroSCORE) at baseline (Table 1), indicat-
ing that these factors cannot be used to predict skeletal
muscle loss. Clinical data for the two groups of patients
are shown in Table 1; the median length of ICU stay was
1 day for non muscle-wasting patients and 2 days for
those with muscle wasting (P = 0.62, Mann-Whitney
test). Further clinical data including indication for car-
diac surgery can be found in the original study and its
online supplement [17].MicroRNAs
miR-133 and -206 were not detectable. miR-16 was
quantified as a control microRNA [21]. No statistical
difference between muscle-wasting and non muscle-
wasting patients was found in plasma concentration of
these microRNAs at baseline, or in the absolute values
at any other time point. Repeated measurements were
therefore expressed and analysed relative to the pa-
tient’s own baseline (fold-change). miR-30b and -499
remained unchanged both between and within groups
over time (Figure 1).ta for non muscle-wasting (n = 19) and muscle-wasting
Muscle-wasting
patients (n = 23)
P-value (t-test, Mann-Whitney#, chi-squared*)
62.0 ± 16.2 0.47
12/11 0.76*
24.7 ± 4.1 0.18
5.5 ± 2.6 0.76
77.3 ± 17.1 0.52
86.8 ± 34.7 0.66
8 0.24*
11 0.97*
3 0.80*
5 0.94*
2 0.66*
10 0.66*
6 0.42*
1 0.21*
2 0.45*
189 ± 68 0.23
2 (1 to 3) 0.62#
9 (8 to 10.5) 0.44#
patients in the muscle-wasting group, therefore, n = 21. Data adapted from
- Chi-squared as appropriate.
Figure 1 Relative plasma microRNA concentration in patients with and without muscle wasting in adult critical care. Relative plasma
microRNA concentration in non muscle-wasting (n = 19) and muscle-wasting patients (those with >9.24% muscle loss; n = 23) pre-operatively
(PO), on day 1 (D1), day 2 (D2) and on day 7 (D7). Data presented as box and whisker plots with median, interquartile ranges and 5 to 95%
percentiles. *P <0.05, **P <0.01, ***P <0.001, repeated measures Freidman’s test with Dunn’s correction for comparison with pre-operative
baseline. #P = 0.03 for comparison between groups with the Kolmogorov-Smirnov test.
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Median fold-change in plasma miR-181a at D2 was 2.15
(IQR 0.40 to 3.15) in those who developed muscle wasting
compared to 1.02 (IQR 0.50 to 1.60) in those who did not
(P = 0.03) (Figure 1). ROC curve analysis for the increase
in D2 miR-181a gave an area under the curve of 0.6. A rise
in miR-181a at D2 greater than 1.7 times baseline gave a
specificity of 91% and sensitivity of 56% for acute muscle
wasting. This cut off resulted in a positive predictive value
of 91% and a negative predictive value of 56%a.
miR-1
miR-1 was significantly elevated at D1 compared to
baseline in both groups (median 4.03 times higher (IQR1.65 to 7.84) in patients with muscle wasting and 5.14
(IQR 1.31to 14.00 in patients with no muscle wasting);
P <0.01 for both). The fold-change increase in plasma
miR-1 was not different between the two groups. miR-
1 returned to baseline by D2 in both groups (Figure 1).
miR-16
miR-16 was significantly reduced at D1 compared to
baseline in both groups (median 0.71 of baseline (IQR
0.21 to 0.92) in patients with muscle wasting, P <0.01,
and median 0.41 of baseline (IQR 0.31 to 0.87) in patients
with no muscle wasting, P <0.05). The fold-change reduc-
tion was not different between the groups and returned to
baseline in both (Figure 1).
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We provide preliminary data that show that following
elective high-risk cardiothoracic surgery, both patients
with and without subsequent muscle wasting exhibited
changes in the circulating microRNA profile. Despite the
low area under the ROC curve (0.6), we found that a
1.7-fold increase in miR-181a was 91% specific for a sub-
sequent reduction in RFCSA, however, its value in ex-
cluding a subsequent reduction in RFCSA was less
striking. These data are preliminary and as with all bio-
marker studies should be repeated in a validation cohort,
and with more frequent time point measures to define
the window after surgery (or admission) with the great-
est clinical utility.
Critique of the method
This is a relatively small study with a limited population
of patients. In evaluating new tests it is important to
avoid scenarios where there is a high pre-test probability
of the condition one is testing for (in this case quadri-
ceps loss assessed by RFCSA) to provide a fair evaluation
of the test. Our disease model included patients with
brief ICU stays and an uncomplicated post-operative
course. Nevertheless, we achieved an approximately
50:50 split between those who developed a reduction in
RFCSA at the seventh post-operative day and those who
did not, suggesting that the model is suitable for evaluat-
ing the test. While this model of acute muscle wasting
following cardiothoracic surgery allowed us to control
for many of the other factors that occur in the critically
ill, and thus, investigate a disease marker that is specific
to muscle wasting, it remains to be seen whether our re-
sults are generalisable to a wider ICU population (in-
cluding both a greater sample size and wider variation in
ICU disease). It may be that these changes are only seen
in this limited cohort of patients. It is also important to
note that the muscle wasting described here was mild,
no patients developed debilitating muscle weakness and
none reached the diagnostic criteria for true ICU-
acquired weakness as set out by Stevens et al. [22]. A
measure of muscle strength and the relationship between
this and muscle wasting and changes in microRNAs
would potentially add to the study, however, we found that
the Medical Research Council (MRC) strength score was
not discriminatory enough (all but four patients scoring
60/60 at 1 week) and handheld dynamometry was limited
by the pain of sternal wounds following surgery; thus, a
more detailed strength evaluation would require use of a
non-volitional technique such as magnetic nerve stimula-
tion [23]. It is possible that in a sicker group of patients a
clearer, stronger or different signal in change in circulating
microRNA profile might have been seen.
miR-16 was measured in this study as a control micro-
RNA. It is widely expressed and in plasma has previouslybeen used to demonstrate that findings in more specific
microRNAs do not result from general changes in
microRNA levels [12,21]. However, miR-16 has recently
been shown to be elevated in the plasma of septic pa-
tients and is increasingly implicated in disease processes
[24]. Our data show a reduction in miR-16 in both
groups of patients. These patients were not septic, but
all patients did experience an inflammatory insult as evi-
denced by a significant rise in CRP in both groups peaking
at day 2 (Table 1). The differences between inflammation
secondary to infection (sepsis) and inflammation without
infection, are increasingly being recognised [24] and our
data support this. Our data also suggest that miR-16 levels
in plasma do change significantly, implying that it is not
appropriate as reference microRNA in these circum-
stances. However, not all microRNAs measured changed
overtime and therefore we feel that the changes observed
represent real rather than methodological differences.
Both groups showed an acute increase in miR-1 at D1 re-
covering to baseline on D2 after surgery. This may be
accounted for by miR-1 being highly expressed in cardiac
as well as in skeletal muscle, and all patients underwent
cardiothoracic surgery [9]. Plasma miR-1 has been found
to be elevated acutely following myocardial damage in
acute coronary syndromes in several different clinical
studies [9] and to be predictive of outcome [25].
Last, although we chose to examine these microRNAs
because of their roles in muscle homeostasis, we do not
know, in these patients, how the changes in plasma level
of these microRNAs reflect the relative expression or
function of these microRNAs in the muscle, and caution
is therefore required in drawing mechanistic conclu-
sions. MicroRNAs circulate in the blood in exosomes or
bound to protein and high-density lipoproteins. The
regulation, specificity and secretion of microRNA into
the circulation is not fully understood [9]. In COPD,
specific microRNAs change in opposite directions in
muscle and plasma, for example, miR-1 was reduced in
the muscle of patients with COPD and reflected muscle
wasting, whereas it was increased in the plasma of the
same patients [12,13], consistent with our observation
that miR181a was reduced in the muscle of patients with
established ICU-acquired weakness [16]. It is also im-
portant to note that as the field of microRNA research
increases there may be other, as yet unknown, micro-
RNA that would be better biomarkers than the ones tar-
geted in this work. Furthermore, there is significant
variability between individuals and the standard errors
are large. The reasons for this are unclear; however,
these variations are in line with those seen in the litera-
ture, where similar fold-change differences in relatively
small numbers of participants are also described [10].
Also, it may be that as our understanding of microRNA
regulation in the circulation improves, normalisation of
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lipid levels, may become relevant and may allow a nor-
mal range be described. However the rise in miR-181a
seen here suggests potential directions for future re-
search especially given its established roles in inflamma-
tion and muscle metabolism [15,26].
Clinical perspective
Our data suggest that a rise in miR-181a early in ICU
admission may have a high specificity for muscle wasting
at 1 week. The high positive predictive value of this test
(91%) allows it to be used to identify at-risk patients.
However, due to the relatively low sensitivity (56%) not
all patients at risk of muscle wasting will be identified,
therefore this test could not be used to exclude a diag-
nosis of acute muscle wasting. Several possible reasons
suggest themselves for the poorer sensitivity than speci-
ficity of this marker. First, mir-181a may indeed have a
mechanistic role; as it is acknowledged that ICU-
acquired weakness is multi-factorial then if mir-181a
were mechanistic, it would only capture cases in which
this mechanism was the major underlying factor. Sec-
ond, while muscle wasting is long-lasting, both in the
ICU and in other clinical scenarios, the miR-181a rise
was not. Thus, it is conceptually possible that patients
who had weakness at D7 but only a small fold-change in
miR-181a at D2 would have had a greater rise had it
been measured, for example, at D4. Last, as circulating,
microRNA levels depend on export of the microRNA
from cells, other factors increasing cell permeability to
this miRNA could contribute to the presence of miR-
181a in the plasma.
Currently there is no effective therapy for muscle atro-
phy beyond ensuring adequate nutrition and facilitating
early exercise and mobilisation. However, there is in-
creasing interest in preventing muscle loss by the appli-
cation of external neuromuscular electrical stimulation.
Similarly new generation anabolic agents are presently
being evaluated in animals, for example, those targeting
the myostatin signalling pathway [27,28]. In developing
translational studies, which bring novel medicines to pa-
tients, it will be useful to stratify patients by the likelihood
of developing subsequent muscle loss and circulating
miR-181a could be useful for this purpose by reducing the
size of a proof-of-concept study.
The biological role of miR-181a is not fully under-
stood. It is expressed in many different tissues and is not
muscle specific. However, miR-181a is essential for re-
generation and differentiation in muscle after tissue in-
jury [15]. miR-181a is expressed highly in differentiating
and regenerating muscle, and by suppression of Homeobox
Protein A11 (HOX-A11) it promotes muscle differentiation
[15]. Furthermore, in other tissues it has been shown to
be involved in the regulation of inflammatory pathways[26,29]. Both of these pathways may be relevant in the re-
sponse of muscle to critical illness [30]. However, miR-
181b has been found to be reduced in blood obtained
from ICU patients with sepsis [31]. Sepsis is certainly a
major aetiological factor in the development of critical
illness-related acute muscle wasting [30] but our patients
were not septic. Furthermore, although miR-181a and
miR-181b are from the same family of microRNAs, and
likely to be co-transcribed, potential differences in their
function are not fully understood [15]. miR-181a is the
major member of the miR-181 family that has been shown
to be functional in human muscle [15].
Conclusion
In conclusion we have evaluated the potential role of
selected microRNAs for the prediction of subsequent
muscle loss in patients undergoing elective high-risk
cardiothoracic surgery. We found that an elevation of
miR-181a may represent a specific marker of quadriceps
wasting, which deserves further prospective evaluation in
larger unselected populations of critically ill patients.
Key messages
 Acute muscle wasting in the critically ill is difficult
to accurately predict and as such the search for a
biomarker of acute muscle wasting in these patients
is important.
 We identify miR-181a as a potential specific biomarker
of acute muscle wasting in the critically ill that deserves
further prospective evaluation.
Endnote
aOf note, in this case the positive predictive value and
specificity, and the negative predictive value and sensi-
tivity are the same numerically because the number of
true positives and true negatives are numerically the
same.
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